Citations

Clear

4207 citation(s) found for "Chen, Yu".

Abstract 1213: Mitochondrial transcriptome profiles associated with clinical responses to CAR-T therapy in aggressive lymphoma.
Wang, Panwen , Tan, Melinda, Schaefers, Christoph, Wu, Chen , Corraes, Andre de Menezes Silva, Regan, Kevin M., Shao, Zuoyi, Audrey, Ma, Khurana, Arushi , Benanni, Nora N, Wang, Y., Hampel, P., Kenderian, Saad J., Paludo, J., Johnston, Patrick B., Villasboas, Jose Caetano, Ansell, Stephen M., dong, Haidong, Li, Ying, Hu, Zeng , Lin, Yi, Turner, Jacqueline A. , Mondello, Patrizia , Tan, Melinda, Schaefers, Christoph , Corraes, Andre De Menezes Silva , Ma, Audrey, Wang, Yucai , Hampel, Paul J. , Paludo, Jonas , Durani, Urshila , Johnston, Patrick B, Ansell, Stephen M. , Dong, Haidong

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1213-1213

10.1158/1538-7445.am2026-1213 Get It

Abstract Introduction: Therapeutic outcomes in B-cell non-Hodgkin’s lymphoma (B-NHL) have substantially improved with the introduction of chimeric antigen receptor T-cell (CAR-T) therapy. Yet, persistent immune dysfunction and underlying metabolic dysregulation remain major obstacles to achieving durable clinical responses in B-NHL. We hypothesize that mitochondrial pathways play a critical role in mediating anti-tumor immunity during CAR-T therapy. Methods: Peripheral blood mononuclear cells were collected from healthy controls (CNTRL, n=5) and patients with advanced stage lymphoma (LYM) who received FDA approved CAR-T (n=32). Samples were collected before lymphodepletion (BL), at peak CAR-T expansion (PK) and one-month post-infusion (M1). Single-cell RNA sequencing was used to interrogate differential mitochondrial gene expression. Samples were obtained from LYM patients with complete remission for >6 months (CR), primary refractory (PD1), or relapsed (PD2) disease. Results: Compared to CNTRLs, LYM patients exhibited reduced expression of cytochrome c oxidase. At BL, CR patients demonstrated broader mitochondrial differential gene expression across all T-cell subsets relative to PD1 and PD2 and showed higher expression of MT-ATP-6, MT-ATP-8, and MT-CO3. Following CAR-T infusion, global mitochondrial gene expression increased across patients corresponding with expansion of CD8 effector T cells (Tem tumor circulating) and activated peripheral memory T cells (Tpm). Certain mitochondrial genes, such as MT-CO1, were durably expressed across LYM patients at BL, PK, and M1 in peripheral and central memory T cells (Tpm, Tcm). At PK, cytochrome c oxidase and ATP synthase genes were upregulated in CR Tpm and Tcm. At M1, MT-ATP-6, MT-ATP-8, MT-CO3 were significantly upregulated in CD8 memory precursor effector T-cells (MPECs) of CR patients compared to both PD1 and PD2. While CR and PD2 patients appeared clinically responsive at M1, CR samples maintained significantly higher MT-ATP-8 expression across T cell subsets (CD8 MPECS, Tpm, Tcm) compared to PD2 (p values 0.008; <0.0001; <0.0001). Conclusions: We report a temporal shift in immunometabolism with CAR-T therapy in LYM. Clinical responders exhibited sustained mitochondrial activity characterized by persistent expression of ATP synthase in CD8 MPECs and cytochrome c oxidase in Tpm and Tcm. In sum, mitochondrial programming may distinguish effective versus dysfunctional T cells and identify targets for therapeutic development. Citation Format: Jacqueline Turner, Panwen Wang, Patrizia Mondello, Melinda Tan, Christoph Schaefers, Chen Wu, Andre de Menezes Silva Corraes, Kevin Regan, Zuoyi Shao, Ma Audrey, Arushi Khurana, Nora N. Benanni, Yucai Wang, Paul Hampel, Saad J. Kenderian, Jonas Paludo, Urshila Durani, Patrick B. Johnston, Jose Caetano Villasboas, Stephen M. Ansell, Haidong Dong, Ying Li, Zeng Hu, Yi Lin. Mitochondrial transcriptome profiles associated with clinical responses to CAR-T therapy in aggressive lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1213.
Abstract 3931: Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung cancer in real world practice.
Prasad, Dhauna Karam, Corraes, Andre De Menezes Silva, Gupta, Malvika , Ma, Audrey, Wu, Chen , Shao, Zuoyi, Reagan, K J, Kamal, Rayaan, Potter, Ashley , Al-Ajmi, Abdullah, Mina, Syeda A. , Taylor, Sykler J., Dimou, A., Parikh, K., Luce, A., Schwecke, Anna, Molina, Julian R , Mansfield, Aaron S., Holmes, Lucy , Dong, Haidong, Lin, Yi, Leventakos, Konstantinos , Corraes, Andre De Menezes Silva , Ma, Audrey, Shao, Zuoyi, Kamal, Rayaan, Al‐Ajmi, Abdullah, Hazim, Antonious , Shanshal, Mohammed , Molina, Julian R. , Mansfield, Aaron S., Smith, Katherine E. , Holmes, Lucy

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 3931-3931

10.1158/1538-7445.am2026-3931 Get It

Abstract Background: Tarlatamab, a Delta-like ligand (DLL3)/CD3-targeted bispecific T-cell engager (TCE) is FDA approved in patients (pts) with extensive stage small cell lung cancer (ES-SCLC), after progression on frontline chemoimmunotherapy. We aimed to evaluate the immune cell profile in pts who received this therapy in standard-of-care (SOC) practice with progression free survival (PFS) less than and greater than two months (mo). Methods: Patients who received tarlatamab at Mayo Clinic Rochester and consented to immuno phenotyping of blood are included in the present study. Immune phenotyping was performed on whole blood by flow cytometry and analyzed by Kaluza. Data analysis was performed with Microsoft Excel and PRISM. Results: Eighteen patients with median age 64 (range 37-79) were included in the study. 66% of our cohort were women and 83% had present or past history of smoking, with an average of 40 pack years (range 26-60). With a median follow-up of 2 months, the median PFS for the cohort was 1.5 mo (range 0.33-2.76 months). 61% (13/18) of patients had PFS <2mo. 39% (5/18) had PFS>2mo and of which, three patients had partial response with one maintaining stable disease and one patient with mixed response. At baseline (BL), there were no difference in T cell, CD4 or CD8 cell count between patients in the PFS<2mo and PFS>2mo groups. Patients with PFS<2mo had higher exhausted CD8 T cells compared to those in the PFS>2mo group (CD8+PD1+TIGIT+CD57+, PFS<3mo vs >3mo, cells/mL: 7.14±4.28, 1.58±1.37, p=0.009). Additionally, when analyzing the B-cell population, the PFS<2mo group had lower percentage of B cells compared to the group with PFS>2mo at baseline (6.0±7.5, 10.4±14, p=0.02). At day 7, the group with PFS<2mo had lower Treg compared to the group with PFS>2mo (2.88±1.38, 4.60±1.47, p=0.02). Also, the PFS<2mo group had an increase of B cells compared to the group with PFS>2mo at day 7(<2mo vs >2mo: 10.0±14, 4.37±3.07, p=0.04). Finally, the group with PFS>2mo had decrease in total monocytes (mono), classical mono, and immunosuppressive cells (PFS<2mo vs >2mo, Mono: 340±347, 253±106, p=0.04. Classical mono: 305±283, 155±109, p=0.02. CD14+HLA-DRneg: 105.8±96, 12±39, p=0.03) compared to the group with PFS<2mo by day 7. While no changes were seen between BL and day 7 for intermediate mono in PFS<2mo group, PFS>2mo group had decreased post treatment intermediate monocytes (BL vs day 7, cells/mL, intermed mono: 32.5±15,17.7±6.2, p=0.03). Conclusion: In this study investigating the SOC outcomes of tarlatamab, early progression was associated with higher presence of exhausted CD8 T cells, B cells, and immunosuppressive monocytes. Analysis of additional patients will be shared at AACR meeting. Citation Format: Dhauna Karam Prasad, Andre De Menezes Silva Corraes, Malvika Gupta, Audrey Ma, Chen Wu, Zuoyi Shao, Kevin Reagan, Rayaan Kamal, Ashley Potter, Abdullah Al-Ajmi, Syeda Mina, Sykler J. Taylor, Antonious Hazim, Anastasios Dimou, Kaushal Parikh, Mohammed Shanshal, Ailsa Luce, Anna Schwecke, Julian Molina, Aaron Mansfield, Katherine Smith, Lucy Holmes, Haidong Dong, Yi Lin, Konstantinos Leventakos. Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung cancer in real world practice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3931.
Abstract 2107: Genomic landscape of melanoma brain metastases: Real-world analysis and comparison with public melanoma cohorts.
Parker, Joseph B., Hamilton, Jakob , Adeoye, Oluwatayo , Kamatham, Saivaishnavi , Tan, Winston, Dimou, Anastasios, Block, Matthew S. , Markovic, Svetomir, Seetharam, ­Mahesh , Dronca, Roxana , Chen, R., Elantably, Dina , Abdelhakeem, Ahmed , Tan, Winston, Dudek, Arkadiusz Z. , Dimou, Anastasios , McWilliams, Robert R. , Markovic, Svetomir

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2107-2107

10.1158/1538-7445.am2026-2107 Get It

Abstract Background: Melanoma brain metastases (MBM) represent a biologically distinct and clinically aggressive subset of melanoma. Comprehensive molecular characterization focused on intracranial disease remains limited. We aimed to define the genomic landscape of MBM and compare these findings with public melanoma datasets. Methods: We retrospectively identified 166 patients with histologically confirmed MBM across Mayo Clinic tri-sites (2011-2025). Molecular testing was performed in 123 patients (74.1%). Comprehensive next-generation sequencing (NGS; ≥300-gene platforms including Tempus, FoundationOne, Caris, NeoGenomics, and MayoComplete Solid Tumor Panel) was available in 41 patients (24.7%). Intermediate-depth profiling using the MayoComplete Melanoma Panel (17 genes) was performed in 21 patients (12.7%), and a targeted 5-gene melanoma driver panel (BRAF, NRAS, KIT, GNAQ, GNA11) in 52 patients (31.3%). cfDNA-based NGS was available in 12 patients (7.2%). Genomic alterations were summarized and benchmarked against TCGA-SKCM and MSK-IMPACT datasets via cBioPortal. We considered assay heterogeneity, as Mayo panels varied in sequencing depth and CNV coverage, and hybrid-capture platforms often under-detect TERT promoter hotspots. Results: Patients had a median age of 67 years, and 63% were male. BRAF mutations occurred in 48.8% (BRAF V600E/K 41.6%; non-V600 7.2%). Additional MAPK alterations included NRAS (17.5%), KIT (5.4%), GNAQ (1.2%), and GNA11 (0.6%). In the comprehensive NGS subset, tumor-suppressor alterations included CDKN2A (17.5%), PTEN (7.8%), NF1 (9.0%), TP53 (8.4%), and TERT promoter mutations (22.9%). Median TMB was 11.55 mut/Mb (IQR 5.0-25.5). Co-alterations included BRAF+CDKN2A (7.2%), BRAF+PTEN (4.2%), NRAS+CDKN2A (4.2%), NRAS+PTEN (1.2%), and CDKN2A+PTEN (3.6%); overall, 18.1% harbored MAPK driver + tumor-suppressor co-alterations. Compared with TCGA and MSK cohorts, MBM showed similar MAPK driver frequencies but fewer MAPK + tumor-suppressor co-alterations and lower CDKN2A, PTEN, and TP53 disruption, alongside a more prevalent of TERT promoter mutations (22.9% vs 7% and 2.1%), which may partly reflect coverage differences. Conclusion: MBM exhibit a distinct genomic profile characterized by reduced tumor-suppressor loss, fewer MAPK-tumor-suppressor co-alterations, and higher prevalence of TERT promoter mutations. While assay heterogeneity limits direct cross-cohort comparisons, these patterns suggest potentially distinct biological features of intracranial melanoma and underscore the need for harmonized, MBM-specific molecular studies to guide therapeutic development. Citation Format: Dina Elantably, Joseph B. Parker, Jakob Hamilton, Ahmed Abdelhakeem, Oluwatayo Adeoye, Saivaishnavi Kamatham, Winston Tan, Arkadiusz Z. Dudek, Anastasios Dimou, Matthew S. Block, Robert McWilliams, Svetomir Markovic, Mahesh Seetharam, Roxana Dronca, Ruqin Chen. Genomic landscape of melanoma brain metastases: Real-world analysis and comparison with public melanoma cohorts [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2107.
Abstract 1184: IHC-based prognostic sub-stratification of ovarian endometrioid carcinoma.
Taengwa, Gamaliel , Atkinson, Hunter J., McCauley, Bryan M. , Armasu, Sebastian M. , Wang, Chen, Doherty, Jennifer A., Goode, Ellen L. , Köebel, Martin, Atkinson, Hunter J., Doherty, Jennifer A. , Harris, Holly R. , Winham, Stacey J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1184-1184

10.1158/1538-7445.am2026-1184 Get It

Abstract Ovarian endometrioid carcinoma (OEC) is the second most common histotype associated with the most favorable prognosis among ovarian carcinomas. Similar to endometrial carcinoma, OEC exhibit significant molecular diversity. We aimed to develop a practical immunohistochemical (IHC) prognosticator by integrating IHC biomarkers with clinical substage, and surgical outcomes. This multi-institutional study included participants with primary invasive OEC from the Alberta Cancer Registry (AOVT), Mayo Clinic, and Disease of the Ovary and their Evaluation Study (DOVE). Pathology review excluded misclassified high-grade serous and mesonephric carcinomas leaving 422 OEC cases (AOVT N=158; DOVE N=143; Mayo N=121) with available tumor biospecimens who did not receive neoadjuvant treatment. Clinical characteristics included age, stage, grade, residual disease and 5-year survival. Clinical risk group was defined by combining stage and residual disease: Low (FIGO stage IA/IB & no macroscopic disease), Intermediate (stage IC-II& no macroscopic disease), High (stage III/IV or macroscopic disease). Tissue microarrays were stained for TP53, PMS2, MSH6, PGR, and CTNNB1 using IHC and were scored by a single pathologist. Tumors were hierarchically categorized as TP53-abnormal (TP53abn)/PGR-loss, mismatch-repair deficient (MMRd, via PMS2 and MSH6), nuclear-CTNNB1 (nCTNNB1), or no-specific-immunohistochemical-profile (NSIP). Overall survival (OS) at 5 years was compared across clinical risk and biomarker groups using Cox regression, adjusted for age and site to generate hazard ratios (HR), and 5-year survival rates (5-YSR). High clinical risk group was associated with worse 5-year OS compared to low & intermediate risk (p<0.0001). Hierarchical IHC biomarker groups were also associated with 5-year OS, adjusted for age and study site (p<0.0001), with consistently worse survival for combined TP53abn/PGR-loss (n=17, HR=6.07, 95% CI 2.78-13.26), PGR-loss only (n=55, HR=4.17, 95% CI 2.19-7.94), TP53abn only (n=29, HR=2.04, 95% CI 0.85-4.90), and better survival for nuclear-CTNNB1 (n=146, HR=0.22, 95% CI 0.07-0.65) compared to NSIP (n=132). Within the low-risk group, MMRd, nCTNNB1, or NSIP had greater than 97% 5-YSR, while OEC with TP53abn/PGR-loss or PR-loss only had less than 75% 5-YSR. Within the intermediate group, only nCTNNB1 exceeded a 5-YSR of greater than 97%. Within the high-risk group, 5YSR for nCTNNB1 OEC was 90.9%, compared to only 16.7% for TP53abn/PGR-loss. This IHC-based algorithm refines prognosis beyond clinical substage. It identifies low-risk patients with unfavorable prognosis (TP53abn/PGRloss, PGR loss only) who may benefit from adjuvant therapy, and also patients with favorable prognosis within the intermediate group for whom adjuvant therapy could be de-escalated. Further patient selection for chemo vs. hormone therapy in the high-risk group may be improved by biomarkers. Citation Format: Gamaliel Taengwa, Hunter J. Atkinson, Bryan M. McCauley, Sebastian M. Armasu, Chen Wang, Jennifer A. Doherty, Holly R. Harris, Ellen L. Goode, Martin Koebel, Stacey J. Winham. IHC-based prognostic sub-stratification of ovarian endometrioid carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1184.
Abstract 1040: Blinded clinical validation of LiquidTME, a cell-free DNA assay for predicting response to immunotherapy by noninvasively profiling the tumor microenvironment
Chaudhuri., Aadel A., Chen, D., Hansen, Tucker , Jarosz, Mirna, Miller, Vincent A. , Newman, Aaron M. , Chaudhuri, Aadel A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1040-1040

10.1158/1538-7445.am2026-1040 Get It

Abstract Background: Combination immune checkpoint inhibitor (ICI) therapy represents a standard-of-care for patients with metastatic melanoma. However, >40% of patients do not respond to treatment and severe immune-related toxicity affects up to 60% of patients. Accordingly, we need more precise ways to select patients for combination ICIs. To address this, we developed LiquidTME, a liquid biopsy method based on Spatial EcoTyper (Cancer Res (2025) 85 (8_Supplement_1): 153) that leverages a deep learning approach to noninvasively assess the tumor microenvironment from cell-free DNA (cfDNA) methylation data. LiquidTME was previously trained to predict ICI response using 78 patients with advanced melanoma treated at Yale University. Here we performed a blinded validation of LiquidTME in coordination with clinicians at Washington University (WashU). Methods: The WashU cohort consisted of pre-ICI plasma from 34 patients with advanced melanoma, each treated with ipilimumab and nivolumab (n=27) or relatlimab and nivolumab (n=7). ICI response was classified as durable clinical benefit (DCB) or no durable benefit (NDB) by a board-certified oncologist. Tumor mutational burden (TMB) was determined for 27 patients using commercial CLIA assays and analyzed as nonsynonymous mutations (mt) per megabase (Mb), using the FDA-approved 10 mt/Mb cutpoint for TMB-high and -low groups. The WashU cohort was sent to a scientific team that was blinded to all clinical and TMB data. Cell-free DNA was extracted from 2 mL plasma per patient and subjected to enzymatic methyl-seq (EM-seq) at a median depth of 15x. LiquidTME was performed on the resulting profiles, yielding a binary response prediction and a continuous response score for each sample. Test results were locked down and returned. Both assays were compared by AUC and two-sided Wilcoxon rank-sum tests for response classification, and Kaplan-Meier analysis for progression-free survival (PFS). Results: Median follow-up time of the cohort was 21.6 months. LiquidTME performed on cycle 1 day 1 pre-ICI plasma significantly stratified PFS with a hazard ratio (HR) of 0.27 (P = 0.005), with LiquidTME(+) patients achieving a median PFS of 1.7 years longer than LiquidTME(-) patients. LiquidTME distinguished DCB from NDB with an AUC of 0.77 (P = 0.007). Similar performance was seen across distinct combination ICI regimens. In patients with TMB data, LiquidTME maintained whole-cohort performance with a PFS HR of 0.30 (P < 0.03; AUC = 0.77). In contrast, TMB high vs. low subsets failed to stratify PFS (HR = 0.49; P = 0.17) or response (AUC = 0.53; P = 0.8). Conclusion: LiquidTME identified durable responders to combination ICI from pretreatment plasma in this blinded validation cohort of melanoma patients. Given its favorable performance, LiquidTME shows promise as a clinical tool to guide personalized immunotherapy decision-making. Citation Format: Aadel A. Chaudhuri, David Y. Chen, Tucker Hansen, Mirna Jarosz, Vincent A. Miller, Aaron M. Newman. Blinded clinical validation of LiquidTME, a cell-free DNA assay for predicting response to immunotherapy by noninvasively profiling the tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1040.
Abstract 94: Liquid biopsy profiling of the tumor microenvironment to determine response to immunotherapy regimens across solid tumors.
Brown, Erin L. , Zhang, W., Hashmi, Ayesha , Olelewe, Chibuzor, Viswanathan, Anushka , Kang, Minji , Jeon, Hyun Soo , Avagyan, Susanna , Bergsagel, Matteo , Schwab, Janella C. , Sachs, Chloe M., Qaium, Faridi , Bacchiocchi, Antonella , Cai, Qingyuan , Gentles, Andrew J. , Graham, Rondell, Orme, Jacob J. , Sznol, Mario, Halaban, Ruth, Chen, D., Newman, Aaron M. , Chaudhuri., Aadel A., Zhang, Wubing , Usmani, Abul , Earland, Noah , Chauhan, Pradeep S. , Steen, Chloé Beate , Alahi, Irfan , Semenkovich, Nicholas P. , Harris, Peter K , Lucas, Peter C. , Fields, Ryan C. , Mansfield, Aaron S. , Halaban, Ruth , Chaudhuri, Aadel A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 94-94

10.1158/1538-7445.am2026-94 Get It

Abstract Background: Spatial cellular ecosystems in the tumor microenvironment (TME) form dynamic signaling hubs that critically influence cancer disease progression and response to therapy, including response to immune checkpoint inhibitors (ICIs). However, tumor sampling bias and the impracticality of acquiring serial tumor biopsies have made it challenging to profile the TME clinically. To address this challenge, we developed Liquid EcoTyper, a multi-analyte AI framework to quantify TME spatial cellular ecosystems—termed spatial ecotypes (SEs)—noninvasively from cell-free DNA (cfDNA) methylation data. Methods: In previous work, we discovered nine spatial ecotypes, including SEs associated with ICI response (e.g., SE7 with benefit, SE4 with resistance), and quantified them from 1,249 bulk tumor RNA-seq profiles of melanoma, non-small cell lung cancer (NSCLC), and bladder cancer (BC) patients (Cancer Res (2025) 85 (8_Supplement_1): 153). Here we trained Liquid EcoTyper, an interpretable deep learning model, to transfer SE profiling to cell-free DNA using CpG methylation profiles. Performance was quantified using simulated and real data, including methylation profiles (EM-seq) of plasma cfDNA paired with tumor biopsy-derived SE levels determined by EM-seq (n=20 pairs) or 10x Visium (n=15 pairs). Clinical outcome prediction was evaluated using pretreatment plasma from patients treated with ICI alone (n=78 melanoma pts), chemotherapy and ICI (n=25 NSCLC pts), and enfortumab vedotin and ICI (n=10 localized muscle-invasive BC (MIBC) pts). Tumor mutational burden (TMB), tumor PD-L1, or circulating tumor DNA (ctDNA) were profiled as a comparator where possible. Results: We observed striking concordance between plasma-derived SE levels and tumor biopsy-confirmed SE levels from the same patients, demonstrating that liquid biopsy analysis of cfDNA methylomes can recapitulate TME spatial biology. Underscoring specificity, no reliable SE signal was detectable from peripheral blood mononuclear cells. In pre-ICI plasma, liquid SE levels were significantly associated with ICI-based response (SE7) versus resistance (SE4) in patients with melanoma, NSCLC, and MIBC, with a mean cross-cancer area under the curve (AUC) of 0.87 for SE7 (range 0.8-0.97) and 0.81 for SE4 (range 0.76-0.85)—far surpassing TMB, tumor PD-L1, and ctDNA in evaluable patients, both in binary analyses of response and multivariable models of survival. Our results also showed potential to predict pathologic complete response in the neoadjuvant setting. Conclusion: Liquid EcoTyper is a scalable noninvasive AI-based framework for spatiotemporal assessment of the TME. By enabling TME-informed risk stratification without surgical biopsies, Liquid EcoTyper has potential to enable more precise and actionable decision making in patients with solid tumors. Citation Format: Erin L. Brown, Wubing Zhang, Abul Usmani, Noah Earland, Ayesha Hashmi, Chibuzor Olelewe, Anushka Viswanathan, Pradeep S. Chauhan, Minji Kang, Chloé B. Steen, Hyun Soo Jeon, Susanna Avagyan, Irfan Alahi, Nicholas P. Semenkovich, Matteo Bergsagel, Janella C. Schwab, Chloe M. Sachs, Faridi Qaium, Peter K. Harris, Antonella Bacchiocchi, Qingyuan Cai, Andrew J. Gentles, Rondell P. Graham, Peter C. Lucas, Ryan C. Fields, Jacob J. Orme, Aaron S. Mansfield, Mario Sznol, Ruth Halaban, David Y. Chen, Aaron M. Newman, Aadel A. Chaudhuri. Liquid biopsy profiling of the tumor microenvironment to determine response to immunotherapy regimens across solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 94.
Abstract 539: Cholesterol triggers chromatin stress to drive senescence and inflammation.
Han, Yiqun, Ouyang, Yaobin, Xu, Hangcheng, Chen, Bin, Yin, Ping , Zhou, Qin , Huang, Jinzhou , Luo, Kuntian, Wu, Zheming , Xiao, Huaping, Tu, Xinyi , Jing, Jiajun, Huang, Xiaofeng, Welliver, M.X., Lou, Zhenkun, Mutter, Robert, Ouyang, Yaobin , Zhu, Shouhai , Xu, Hangcheng , Yin, Ping, Huang, Jinzhou, Kloeber, Jake A. , Lou, Zhenkun , Mutter, Robert W.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 539-539

10.1158/1538-7445.am2026-539 Get It

Abstract Cholesterol has long been viewed as a structural component of cellular membranes, yet its role in DNA damage response remains poorly defined. Here, we show that ionizing radiation (IR) induces broad transcriptional upregulation of cholesterol biosynthesis, transport, and storage pathways, leading to sustained intracellular accumulation of cholesterol. BODIPY-cholesterol imaging, Filipin III staining, and quantitative subcellular fractionation confirmed selective nuclear enrichment of cholesterol following IR, coinciding with extensive chromatin remodeling. Proteomic profiling of cholesterol-interacting proteins revealed a strong enrichment of chromatin-associated factors, suggesting a previously unrecognized lipid-chromatin interface in irradiated cells. Functionally, cholesterol accumulation promoted chromatin compaction and repressive histone modification patterns, impairing DNA damage sensing and checkpoint activation despite increased underlying DNA lesions. These alterations facilitated aberrant mitotic entry, formation of cytoplasmic chromatin fragments (CCFs), and activation of cGAS-STING-NF-κB signaling. Cholesterol exposure ultimately diverted damaged cells toward a senescent fate, marked by Lamin B1 loss, p21 induction, and a robust senescence-associated secretory phenotype (SASP) enriched for IL-1 and TNF family cytokines. In vivo, dietary cholesterol exacerbated radiation-induced inflammation and weakened systemic anti-tumor immunity. Transcriptomic analyses of immunotherapy-treated patients revealed that tumors enriched for cholesterol import and senescence signatures were associated with poor response to PD-L1 blockade and worse survival. Together, these findings identify a cholesterol-chromatin-senescence axis that links metabolic remodeling to defective DNA damage signaling and immune suppression after radiation, highlighting cholesterol metabolism as a potential therapeutic vulnerability in cancer therapy. Citation Format: Yiqun Han, Yaobin Ouyang, Shouhai Zhu, Hangcheng Xu, Bin Chen, Ping Yin, Qin Zhou, Jinzhou Huang, Kuntian Luo, Zheming Wu, Huaping Xiao, Xinyi Tu, Jake A. Kloeber, Jiajun Jing, Xiaofeng Huang, Meng Xu Welliver, Zhenkun Lou, Robert Mutter. Cholesterol triggers chromatin stress to drive senescence and inflammation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 539.
When estrogen sparks clotting: the lactoferrin-FXI link
Chen, Dong

Mayo Clinic

Blood | April 2, 2026 | Volume: 147 | Issue: 14 | Pages: 1518-1519

10.1182/blood.2025032335 | PMID 41926142 Get It